Funding Opportunity PAR-25-269 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same target engagement measure; or study the impact of the natural product in a population that is more responsive,

Funding Opportunity PAR-25-300 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support the investigation of HIV-1 Envelope (Env) cell surface expression, the structural mechanism of biologic-mediated cell killing, and the development of novel approaches to enhance the recognition and elimination of Env-expressing, HIV-1 infected cells. These studies are expected to inform the development of immunotherapies and targeted vaccines for HIV-1 prevention and cure.

Funding Opportunity PAR-25-266 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Funding Opportunity PAR-25-265 from the NIH Guide for Grants and Contracts. This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Competitive: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus London, United Kingdom

Competitive: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus Cambridge, United Kingdom

Competitive: The Institute Of Cancer Research: Key Information Salary: £41,607* to £48,224 Dependent on relevant Postdoctoral experience. Future progression is based on annual performance review. London, United Kingdom

Competitive: BenevolentAI: We are looking for a talented Senior Bioinformatics Data Scientist to join the Product & Tech division. You will work in a cross-functional team apply London, United Kingdom

£48,788 - £56,747 : 37 hours per week: Public Health Scotland: An exciting opportunity has arisen within the Clinical and Protecting Health Directorate of PHS Edinburgh/Glasgow

£38,082 - £45,622: Barts Cancer Institute , Queen Mary University London: About the Role The Postdoctoral research Assistant will join the teams led by Dr Rouault-Pierre & Dr Ana Rio-Machin (Nat Com 2015, 2019, 2020; Cell S London, United Kingdom

Competitive: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus Cambridge, United Kingdom

Funding Opportunity PAR-25-192 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Notice NOT-CA-25-012 from the NIH Guide for Grants and Contracts

Notice NOT-HL-24-034 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-193 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Funding Opportunity PA-25-163 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

Funding Opportunity PA-25-245 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

£37,472 - £45,622 per annum: Barts Cancer Institute , Queen Mary University London: About the Role A fully funded Postdoctoral Research Assistant position is available to join a team led by Prof Susana Godinho to study how amplified London, United Kingdom

Funding Opportunity PAR-25-134 from the NIH Guide for Grants and Contracts. The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutionsis to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F and A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information.

Notice NOT-MH-25-095 from the NIH Guide for Grants and Contracts